||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Real-Time news about York Pharma (London Stock Exchange): 0 recent articles
|York Pharma Daily Update: York Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YRK. The last closing price for York Pharma was 3.25p.|
York Pharma has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 61,399,715 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of York Pharma is £1,995,490.74.
|topinfo: KiKi...Not long to wait now, they will be back soon. Just remember this was priced to go bust, either we get fully taken over or Re-Financed, either way share price will go up significantly. Looking at ULU I would rather go for the re-financing deal and that way the new CEO Richard Anderson who is the biggest single shareholder can rebuild the business and return real value to shareholders. If it comes back then it will be one of two deals as mentioned, either or will have massive impact on share price I personally would like to see option 2.|
|kiki14p: Thanks Topinfo & BB80 reassuring comments..Not spoken to RA but heard it all before from previous CEO... TS in conversation was also very very optimistic about the company (maybe too much!) - won't again base my investment decisions on how enthusiastic a director is, does not mean they can pull it off and grow the company and share price on enthusiasm alone!|
|ursamajorra: RNS Number : 1570O
York Pharma plc
02 March 2009
Not for release, publication or distribution in whole or in part, in or into the
United States, Canada,
Australia, Japan or the Republic of Ireland
York Pharma plc
Statement concerning Possible Offer and Rule 2.10 announcement
The Board of the Company notes the recent movement in the Company's share price
and confirms that the Company has made an approach to a potential offeror which
may or may not lead to an offer being made for the Company. The Board of the
Company, which is being advised by Collins Stewart Europe Limited, wishes to
stress that these discussions are at a very early stage and there can be no
certainty that this approach will lead to an offer being made for the Company.|
|handycam: Sinclair and York are two very similar peas in a pod, though the former has a reasonable business it would seem. Share price trajectories are carbon copies.|
i fully agree that the share price has discounted abasol, but why would it not be approved by the mhra?
|bignads: Handycam. That question did cross my mind. However, I would imagine there are a few people willing to sell given the collapse in the share price over the last eighteen months, so it's hardly surprising. To be honest, If I get it wrong I'm going to lose 15 pence max. if I get it right, I stand to make 45 pence per share minimum. I see the two scenarios as equal risk, so that's not a bad position to be in. What's your view of fair value. 5p?|
|bignads: Oh, well, I've dipped my toe in the water.
20,000 at 15 pence seems like a steal to me. believe the latest 6-month results should be a boost to the share price as revenues start to feed into the bottom line. Not expecting profits just yet, but reduced losses and a positive outlook from the firm should do it...|
|kiki14p: there has been little development news this year... Abasol approval would be nice for the share price along with a US licencing deal.....here's hoping they finally arrive soon!|
|topvest: you bet - still no news and the share price graph looks like it is heading to zero!|
|topvest: OOPS...looks like they are having problems raising the money now the share price has fallen.|
York Pharma share price data is direct from the London Stock Exchange